Aminolevulinic acid and Sulfasalazine Delayed-Release Tablets
Determining the interaction of Aminolevulinic acid and Sulfasalazine Delayed-Release Tablets and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.GENERALLY AVOID: Patients exposed to photosensitizing agents may be at increased risk of a phototoxic skin reaction (severe sunburn) during use of aminolevulinic acid. MANAGEMENT: Photosensitizing agents (e.g., fluoroquinolones, phenothiazines, retinoids, sulfonamides, sulfonylureas, tetracyclines, thiazide diuretics, griseofulvin, St. John's wort) and topical preparations containing aminolevulinic acid should generally not be administered for 24 hours before and after oral administration of aminolevulinic acid. Some authorities recommend avoiding exposure to any photosensitizing agent for up to 2 weeks after oral administration of aminolevulinic acid, if possible. Patients should also avoid exposure of the eyes and skin to sunlight or bright indoor lights (e.g., examination lamps, operating room lamps, tanning beds, lights at close proximity) for 48 hours after receiving aminolevulinic acid. References "Product Information. Gleolan (aminolevulinic acid)." NX Development Corp, Lexington, KY.
Professional:GENERALLY AVOID: Patients exposed to photosensitizing agents may be at increased risk of a phototoxic skin reaction (severe sunburn) during use of aminolevulinic acid.
MANAGEMENT: Photosensitizing agents (e.g., fluoroquinolones, phenothiazines, retinoids, sulfonamides, sulfonylureas, tetracyclines, thiazide diuretics, griseofulvin, St. John's wort) and topical preparations containing aminolevulinic acid should generally not be administered for 24 hours before and after oral administration of aminolevulinic acid. Some authorities recommend avoiding exposure to any photosensitizing agent for up to 2 weeks after oral administration of aminolevulinic acid, if possible. Patients should also avoid exposure of the eyes and skin to sunlight or bright indoor lights (e.g., examination lamps, operating room lamps, tanning beds, lights at close proximity) for 48 hours after receiving aminolevulinic acid.
- "Product Information. Gleolan (aminolevulinic acid)." NX Development Corp, Lexington, KY.
Generic Name: aminolevulinic acid
Brand name: Gleolan
Synonyms: n.a.
Generic Name: sulfasalazine
Brand name: Azulfidine, Azulfidine EN-tabs, Sulfazine
Synonyms: Sulfasalazine, SulfaSALAzine
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Aminolevulinic acid-Sulfasalazine Tablets
- Aminolevulinic acid-Sulfatol 10-4 Cleansing Pads
- Aminolevulinic acid-Sulfatol C Cream
- Aminolevulinic acid-Sulfatol Cleanser
- Aminolevulinic acid-Sulfatol Gel
- Aminolevulinic acid-Sulfatol SS Cream
- Sulfasalazine Delayed-Release Tablets-Aminolevulinic Acid (Systemic)
- Sulfasalazine Delayed-Release Tablets-Aminolevulinic Acid Gel
- Sulfasalazine Delayed-Release Tablets-Aminolevulinic Acid Hydrochloride
- Sulfasalazine Delayed-Release Tablets-Aminolevulinic Acid Solution
- Sulfasalazine Delayed-Release Tablets-Aminolevulinic acid topical
- Sulfasalazine Delayed-Release Tablets-Aminomine